慢性胰腺炎抗炎和抗纤维化治疗的研究进展  

Research progress on anti-inflammatory and anti-fibrotic therapy for chronic pancreatitis

作　　者：谭欣 王鹏源 胡良皞 Tan Xin;Wang Pengyuan;Hu Lianghao(Department of Gastroenterology,the First Affiliated Hospital,Naval Medical University,Shanghai 200433,China;Department of Gastroenterology,the 981st Hospital of Joint Logistic Support Force,Chengde 067000,China)

机构地区：[1]海军军医大学第一附属医院消化内科,上海200433 [2]联勤保障部队第九八一医院消化内科,河北承德067000

出　　处：《中华消化病与影像杂志（电子版）》2024年第4期289-296,共8页Chinese Journal of Digestion and Medical Imageology(Electronic Edition)

基　　金：国家自然科学基金(82070664,82270679,82104257);上海市曙光计划(20SG36);上海申康医院发展中心新兴前沿项目(SHDC12021107)。

摘　　要：慢性胰腺炎(CP)以胰腺慢性炎症及纤维化为特征,胰腺腺泡细胞损伤、星状细胞活化及炎症细胞浸润共同影响疾病进程。长期以来,CP治疗以控制症状和防治并发症为主,临床上暂无干预疾病发展的有效药物。因此,寻找可干预的分子靶点和药物是CP研究的重要方向。本文综述了CP的发病机制及抗炎抗纤维化治疗研究进展,以期为CP的治疗提供更多选择。Chronic pancreatitis(CP)is characterized by chronic inflammation and fibrosis of the pancreas,with pancreatic acinar cell injury,stellate cell activation,and inflammatory cell infiltration collectively influencing the disease process.For a long time,the treatment of CP has focused on controlling symptoms and preventing complications,with no effective drugs available for intervening in the disease progression clinically.Therefore,the search for molecular targets and drugs that could be intervened is an important direction in CP research.This article reviews the pathogenesis of CP and the progress in anti-inflammatory and anti-fibrotic treatment research,aiming to provide more treatment options for CP.

关 键 词：慢性胰腺炎 炎症 纤维化 胰腺星状细胞 药物干预 

分 类 号：R576[医药卫生—消化系统]